Stock BPMUF BASILEA PHARMACEUTICA AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Basilea Pharmaceutica AG OTC Markets

Equities

BPMUF

CH0011432447

Market Closed - OTC Markets
Other stock markets
 18:51:48 20/05/2024 BST 		5-day change 1st Jan Change
48.15 USD +8.32% Intraday chart for Basilea Pharmaceutica AG 0.00% +17.44%
05-16 Basilea Pharmaceutica Receives Milestone Payment from Pfizer for Cresemba Sales MT
05-16 Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 49% by 2026.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BASILEA PHARMACEUTICA AG Stock Basilea Pharmaceutica AG
+17.44% 582M -
MODERNA, INC. Stock Moderna, Inc.
+43.36% 58.06B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 40.53B
B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.99B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.7B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.56B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.98B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.17B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.92B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BSLN Stock
  4. BPMUF Stock
  5. Ratings Basilea Pharmaceutica AG